News for Palatin Technologies, Inc. (PTN)

PR NewswireCRANBURY, N.J., April 14, 2025 Company working aggressively to regain complianceCommon stock to continue to trade on NYSE American during the ap

Palatin Technologies, under the ticker (PTN), has filed a formal appeal against the NYSE Regulation's decision to delist its common stock. During the appeal pro

Palatin Technologies (PTN) appeals NYSE American delisting notice; stock continues to trade during appeal process. Company enacts financial strengthenin

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-i...

PR NewswireCRANBURY, N.J., April 10, 2025 CRANBURY, N.J., April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a

PR NewswireCRANBURY, N.J., April 10, 2025 Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients w

71% of patients in the Phase 2b study demonstrated a >30% reduction in urine protein to creatinine ratio (UP/Cr), indicating improved kidney function. T

PR NewswireCRANBURY, N.J., March 28, 2025 Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatmen

PR NewswireCRANBURY, N.J., March 25, 2025 Initiated IND-enabling toxicology programIND submission planned for 4Q25; Clinical data expected in 1H26CRANBURY,

Strategic Acquisition by ARMISTICE CAPITAL, LLC (Trades, Portfolio) On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a noteworthy trans

Palatin Technologies, Inc. (NYSE:PTN) Q2 2025 Earnings Conference Call February 13, 2024 11:00 AM ETCompany ParticipantsCarl Spana - CEO and...

PR NewswireCRANBURY, N.J., Feb. 13, 2025 Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDat

PR NewswireCRANBURY, N.J., Feb. 7, 2025 CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Com

Hong Kong-based Millennium Group International Holdings Limited (MGIH) is up over 153 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

PR NewswireCRANBURY, N.J., Dec. 16, 2024 CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "C

PR NewswireCRANBURY, N.J., Nov. 25, 2024 Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to

Palatin Technologies, Inc. (NYSE:PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ETCompany ParticipantsCarl Spana - CEO and...

Gross Product Sales (Q4 2024): $0 (due to the sale of Vyleesi rights).Gross Product Sales (Q4 2023): $4.1 million.Net Product Revenue (Q4 2023): $1.8 million.G

Oct 01, 2024 / 03:00PM GMTOperator Greetings. Welcome to Palatin's fourth-quarter and fiscal year-end 2024 operating results conference call. (Operator Instruct